Inside the funding round driving the shift to intelligent construction fleets
Updated
February 7, 2026 2:12 PM
Aerial shot of an excavator. PHOTO: UNSPLASH
Bedrock Robotics has raised US$270 million in Series B funding as it works to integrate greater automation into the construction industry. The round, co-led by CapitalG and the Valor Atreides AI Fund, values the San Francisco-based company at US$1.75 billion, bringing its total funding to more than US$350 million.
The size of the investment reflects growing interest in technologies that can change how large infrastructure and industrial projects are built. Bedrock is not trying to reinvent construction from scratch. Instead, it is focused on upgrading the machines contractors already use—so they can work more efficiently, safely and consistently.
Founded in 2024 by former Waymo engineers, Bedrock develops systems that allow heavy equipment to operate with increasing levels of autonomy. Its software and hardware can be retrofitted onto machines such as excavators, bulldozers and loaders. Rather than relying on one-off robotic tools, the company is building a connected platform that lets fleets of machines understand their surroundings and coordinate with one another on job sites.
This is what Bedrock calls “system-level autonomy”. Its technology combines cameras, lidar and AI models to help machines perceive terrain, detect obstacles, track work progress and carry out tasks like digging and grading with precision. Human supervisors remain in control, monitoring operations and stepping in when needed. Over time, Bedrock aims to reduce the amount of direct intervention those machines require.
The funding comes as contractors face rising pressure to deliver projects faster and with fewer available workers. In the press release, Bedrock notes that the industry needs nearly 800,000 additional workers over the next two years and that project backlogs have grown to more than eight months. These constraints are pushing firms to explore new ways to keep sites productive without compromising safety or quality.
Bedrock states that autonomy can help address those challenges. Not by removing people from the equation—but by allowing crews to supervise more equipment at once and reduce idle time. If machines can operate longer, with better awareness of their environment, sites can run more smoothly and with fewer disruptions.
The company has already started deploying its system in large-scale excavation work, including manufacturing and infrastructure projects. Contractors are using Bedrock’s platform to test how autonomous equipment can support real-world operations at scale, particularly in earthmoving tasks that demand precision and consistency.
From a business standpoint, the Series B funding will allow Bedrock to expand both its technology and its customer deployments. The company has also strengthened its leadership team with senior hires from Meta and Waymo, deepening its focus on AI evaluation, safety and operational growth. Bedrock says it is targeting its first fully operator-less excavator deployments with customers in 2026—a milestone for autonomy in complex construction equipment.
In that context, this round is not just about capital. It is about giving Bedrock the runway to prove that autonomous systems can move from controlled pilots into everyday use on job sites. The company bets that the future of construction will be shaped less by individual machines—and more by coordinated, intelligent systems that work alongside human crews.
Keep Reading
A new bet on early heart failure detection and why women’s health is at the center.
Updated
January 8, 2026 6:28 PM
A doctor holding an artificial heart model. PHOTO: ADOBE STOCK
Heart disease does not always announce itself clearly, especially in women. Many of the symptoms are ordinary, including fatigue, shortness of breath and swelling. These signs are frequently dismissed or explained away. As a result, many women are diagnosed late, when treatment options are narrower and outcomes are worse. That diagnostic gap is the context behind a recent investment involving Ultromics and the American Heart Association’s Go Red for Women Venture Fund.
Ultromics is a health technology company that uses artificial intelligence to help doctors spot early signs of heart failure from routine heart scans. It has received a strategic investment from the American Heart Association’s Go Red for Women Venture Fund.
The focus of the investment is a long-standing blind spot in cardiac care. Heart failure with preserved ejection fraction, or HFpEF, affects millions of people worldwide, with women disproportionately impacted. It is one of the most common forms of heart failure, yet also one of the hardest to diagnose. Studies even show women are twice as likely as men to develop the condition and around 64% of cases go undiagnosed in routine clinical practice.
Ultromics works with a tool most patients already experience during heart care: the echocardiogram. There is no new scan and no added burden for patients. Its software analyzes standard heart ultrasound images and looks for subtle patterns that point to early heart failure. The goal is clarity. Give clinicians better signals earlier, before the disease advances.
“Heart failure with preserved ejection fraction is one of the most complex and overlooked diseases in cardiology. For too long, clinicians have been expected to diagnose it using tools that weren't built to detect it and as a result, many patients are identified too late,” said Ross Upton, PhD, CEO and Founder of Ultromics. “By augmenting physicians' decision making with EchoGo, we can help them recognize disease at an earlier stage and treat it more effectively.”
The stakes are high. Research suggests women are twice as likely as men to develop the condition and that a majority of cases are missed in routine clinical practice. That delay matters. New therapies can reduce hospitalizations and improve survival, but only if patients are diagnosed in time.
This is why early detection has become a priority for mission-driven investors. “Closing the diagnostic gap by recognizing disease before irreversible damage occurs is critical to improving health for women—and everyone,” said Tracy Warren, Senior Managing Director, Go Red for Women Venture Fund. “We are gratified to see technologies, such as this one, that are accepted by leading institutions as advances in the field of cardiovascular diagnostics. That's the kind of progress our fund was created to accelerate.”
Ultromics’ platform is already cleared by regulators for clinical use and is being deployed in hospitals across the US and UK. The company says its technology has analyzed hundreds of thousands of heart scans, helping clinicians reach clearer conclusions when traditional methods fall short.
Taken together, the investment reflects a broader shift in healthcare. Attention is shifting earlier—toward detection instead of reaction. Toward tools that fit into existing care rather than complicate it. In this case, the funding is not about introducing something new into the system. It is about seeing what has long been missed—and doing so in time.